Skip to main content
. 2016 Oct;101(10):1200–1207. doi: 10.3324/haematol.2016.144949

Figure 2.

Figure 2.

Outcome of all the 130 enrolled patients. The estimated 30-month overall survival was 99% (95% CI, 91–100%), the 30-month estimated progression-free survival was 96% (95% CI, 89–98%), the estimated 30-month survival without treatment discontinuation was 76% (95% CI, 67–83%).